<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Rev Paul Pediatr</journal-id>
      <journal-id journal-id-type="iso-abbrev">Rev Paul Pediatr</journal-id>
      <journal-title-group>
        <journal-title>Revista Paulista de Pediatria</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0103-0582</issn>
      <issn pub-type="epub">1984-0462</issn>
      <publisher>
        <publisher-name>Sociedade de Pediatria de S&#xE3;o Paulo</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24676202</article-id>
      <article-id pub-id-type="pmc">4183003</article-id>
      <article-id pub-id-type="publisher-id">S0103-05822014000100144</article-id>
      <article-id pub-id-type="doi">10.1590/S0103-05822014000100021</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Acute liver failure in a term neonate after repeated paracetamol
administration</article-title>
        <trans-title-group xml:lang="es">
          <trans-title>Falencia hep&#xE1;tica aguda en neonato a t&#xE9;rmino despu&#xE9;s de la ingesti&#xF3;n de
dosis repetidas de paracetamol</trans-title>
        </trans-title-group>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Bucaretchi</surname>
            <given-names>F&#xE1;bio</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fernandes</surname>
            <given-names>Carla Borrasca</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Branco</surname>
            <given-names>Ma&#xED;ra Migliari</given-names>
          </name>
          <xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Capitani</surname>
            <given-names>Eduardo Mello De</given-names>
          </name>
          <xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Hyslop</surname>
            <given-names>Stephen</given-names>
          </name>
          <xref ref-type="aff" rid="aff4">
<sup>4</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Caldas</surname>
            <given-names>Jamil Pedro S.</given-names>
          </name>
          <xref ref-type="aff" rid="aff5">
<sup>5</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Moreno</surname>
            <given-names>Carolina Ara&#xFA;jo</given-names>
          </name>
          <xref ref-type="aff" rid="aff6">
<sup>6</sup>
</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Porta</surname>
            <given-names>Gilda</given-names>
          </name>
          <xref ref-type="aff" rid="aff7">
<sup>7</sup>
</xref>
        </contrib>
      </contrib-group>
      <aff id="aff1"><label>1</label>Departamento de Pediatria da Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Unicamp,
Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff2"><label>2</label>Centro de Controle de Intoxica&#xE7;&#xF5;es da Faculdade de Ci&#xEA;ncias M&#xE9;dicas da
Unicamp, Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff3"><label>3</label>Departamento de Cl&#xED;nica M&#xE9;dica da Faculdade de Ci&#xEA;ncias M&#xE9;dicas da
Unicamp, Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff4"><label>4</label>Departamento de Farmacologia da Faculdade de Ci&#xEA;ncias M&#xE9;dicas da
Unicamp, Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff5"><label>5</label>Unidade de Terapia Intensiva Neonatal do Hospital da Mulher Professor
Doutor Jos&#xE9; Aristodemo Pinotti da Unicamp, Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff6"><label>6</label>Programa de Gen&#xE9;tica Perinatal do Hospital da Mulher Professor Doutor
Jos&#xE9; Aristodemo Pinotti da Unicamp, Campinas, SP, <country>Brasil</country></aff>
      <aff id="aff7"><label>7</label>Departamento de Pediatria da Faculdade de Medicina da Universidade de
S&#xE3;o Paulo (USP), S&#xE3;o Paulo, SP, <country>Brasil</country></aff>
      <author-notes>
        <corresp id="c01">Endere&#xE7;o para correspond&#xEA;ncia: F&#xE1;bio Bucaretchi Rua Tess&#xE1;lia Vieira de
Camargo, 126 - Cidade Universit&#xE1;ria Zeferino Vaz CEP 13083-887 - Campinas/SP E-mail:
<email>bucaret@fcm.unicamp.br</email></corresp>
        <fn fn-type="conflict">
          <p>Conflito de interesse: nada a declarar </p>
        </fn>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <month>3</month>
        <year>2014</year>
      </pub-date>
      <volume>32</volume>
      <issue>1</issue>
      <fpage>144</fpage>
      <lpage>148</lpage>
      <history>
        <date date-type="received">
          <day>01</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>5</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/3.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <sec>
          <title>Objective:</title>
          <p> Severe hepatotoxicity caused by paracetamol is rare in neonates. We report a case
of paracetamol-induced acute liver failure in a term neonate. </p>
        </sec>
        <sec>
          <title>Case description:</title>
          <p> A 26-day-old boy was admitted with intestinal bleeding, shock signs, slight liver
enlargement, coagulopathy, metabolic acidosis (pH=7.21; bicarbonate: 7.1mEq/L),
hypoglycemia (18mg/dL), increased serum aminotransferase activity (AST=4,039IU/L;
ALT=1,087IU/L) and hyperbilirubinemia (total: 9.57mg/dL; direct: 6.18mg/dL) after
receiving oral paracetamol (10mg/kg/dose every 4 hours) for three consecutive days
(total dose around 180mg/kg; serum concentration 36-48 hours after the last dose
of 77&#xB5;g/ mL). Apart from supportive measures, the patient was successfully treated
with intravenous N-acetylcysteine infusion during 11 consecutive days, and was
discharged on day 34. The follow-up revealed full recovery of clinical and of
laboratory findings of hepatic function. </p>
        </sec>
        <sec>
          <title>Comments:</title>
          <p> The paracetamol pharmacokinetics and pharmacodynamics in neonates and infants
differ substantially from those in older children and adults. Despite the reduced
rates of metabolism by the P-450 CYP2E1 enzyme system and the increased ability to
synthesize glutathione - which provides greater resistance after overdoses -, it
is possible to produce hepatotoxic metabolites (N-acetyl-p-benzoquinone) that
cause hepatocellular damage, if glutathione sources are depleted. Paracetamol
clearance is reduced and the half-life of elimination is prolonged. Therefore, a
particular dosing regimen should be followed due to the toxicity risk of
cumulative doses. This report highlights the risk for severe hepatotoxicity in
neonates after paracetamol multiple doses for more than two to three days. </p>
        </sec>
      </abstract>
      <trans-abstract xml:lang="es">
        <sec>
          <title>Objetivo:</title>
          <p> La hepatotoxicidad grave inducida por el paracetamol es muy rara en neonatos. Se
relata el caso de un neonato a t&#xE9;rmino que desarroll&#xF3; falencia hep&#xE1;tica aguda
despu&#xE9;s del uso de paracetamol. </p>
        </sec>
        <sec>
          <title>Descripci&#xF3;n del caso:</title>
          <p> Ni&#xF1;o, 26 d&#xED;as, admitido con sangrado intestinal, se&#xF1;ales de choque, discreta
hepatomegalia, coagulopat&#xED;a, acidosis metab&#xF3;lica (pH=7,21; bicarbonato: 7,1mEq/L),
hipoglucemia (18mg/dL), aumento de las aminotransferasas s&#xE9;ricas (AST=4.039UI/L;
ALT=1.087UI/L) e hiperbilirrubinemia (total: 9,75mg/dL; directa: 6,18mg/dL),
despu&#xE9;s del uso de paracetamol por v&#xED;a oral (10mg/kg/dosis a cada cuatro horas)
durante tres d&#xED;as consecutivos (dosis alrededor de 180mg/kg; nivel s&#xE9;rico de 36-48
horas despu&#xE9;s de la &#xFA;ltima dosis de 77&#xB5;g/mL). Adem&#xE1;s de las medidas de soporte, el
paciente fue tratado con N-acetilciste&#xED;na (infusi&#xF3;n intravenosa continua por 11
d&#xED;as consecutivos), recibiendo alta despu&#xE9;s de 34 d&#xED;as de internaci&#xF3;n. El
seguimiento mostr&#xF3; recuperaci&#xF3;n cl&#xED;nica y de los par&#xE1;metros laboratoriales de la
funci&#xF3;n hep&#xE1;tica. </p>
        </sec>
        <sec>
          <title>Comentarios</title>
          <p>: La farmacocin&#xE9;tica y la farmacodin&#xE1;mica del paracetamol en neonatos y lactantes
j&#xF3;venes (menores de un a&#xF1;o) difieren substancialmente de ni&#xF1;os m&#xE1;s grandes y
adultos. A pesar de que las tasas de metabolismo del sistema enzim&#xE1;tico P-450
CYP2E1 est&#xE1;n reducidas y la capacidad de generar glutati&#xF3;n, aumentada -
confiriendo m&#xE1;s protecci&#xF3;n despu&#xE9;s de superdosis -, existe la posibilidad de
producci&#xF3;n de metab&#xF3;litos hepatot&#xF3;xicos (N-acetil-pbenzoquinoneimina) que
determinan lisis celular, caso se agoten las reservas de glutati&#xF3;n. La depuraci&#xF3;n
es reducida y la media vida de la eliminaci&#xF3;n, alargada, recomend&#xE1;ndose posolog&#xED;a
distinta por el riesgo de toxicidad de dosis cumulativas. El presente relato
subraya el riesgo de hepatotoxicidad grave en neonatos despu&#xE9;s del uso continuo de
paracetamol por m&#xE1;s de dos a tres d&#xED;as. </p>
        </sec>
      </trans-abstract>
      <kwd-group>
        <kwd>acetaminophen</kwd>
        <kwd>liver failure</kwd>
        <kwd>infant, newborn</kwd>
        <kwd>N-acetylcysteine</kwd>
      </kwd-group>
      <counts>
        <table-count count="1"/>
        <ref-count count="21"/>
        <page-count count="1305"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>Paracetamol (N-acetyl-p-aminophenol) is a widely used analgesic and antipyretic in
children; however, toxic exposures are rare in neonates. Toxic exposures may occur via
the placenta, resulting from intentional ingestion of overdoses of paracetamol by
mothers in the 24 hours preceding delivery<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup>, due to isolated oral<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>)</sup> or intravenous dosing errors (propacetamol, pro-drug of paracetamol, not
available in Brazil)<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>, in general, on the order of 10 times the therapeutic dose, or due to
repeated doses orally<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. </p>
      <p>The severe hepatotoxicity induced by paracetamol, with or without acute liver failure,
is almost not described in the neonatal period. In a review of 97 cases of acute liver
failure in patients aged &lt;17 years, in two regional reference units of liver
transplantation in the United Kingdom (1991-2000), there were no cases of liver failure
by medications in the neonatal group (n=17; metabolic diseases - ten cases; infectious
diseases - seven cases). However, paracetamol was the main product associated with liver
failure (14 out of 19 cases), particularly in the age group older than 5 years (n=11),
resulting in seven deaths<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. Another study analyzed a series of 51 children and adolescents who
developed hepatotoxicity induced by paracetamol (45 by isolated overdose and six by
repeated and cumulative doses), all with serum levels of aspartate aminotransferase
(AST) or alanine aminotransferase (ALT) &gt;1,000UI/L, and 11 progressed to liver
failure (encephalopathy and/or coagulopathy). Among these, six were submitted to liver
transplantation - two survived - and the other five died waiting for transplantation.
The youngest patient in this series was 10 months old<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup>. </p>
      <p>In an extensive review conducted by Arana <italic>et al</italic>, regarding the period
from 1978 to 2001, no cases of acetaminophen poisoning by direct administration in
neonates were reported<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>. In 2007, Walls <italic>et al </italic>described the first case of liver
failure in a term neonate with 4 days of life after the use of paracetamol orally for 3
consecutive days (weight 3.1kg; 26mg/kg/dose every 4 hours on the 1st day; 13mg/kg/dose
every 4 hours on the 2nd and 3rd days; total cumulative dose of approximately 312mg/kg),
prescribed as an analgesic postoperatively after a circumcision performed on the 1st day
of life, detecting serum level of acetaminophen of 109.8&#xB5;g/mL, 16 hours after the last
dose. The patient showed complete recovery after continuous intravenous infusion of
N-acetylcysteine for 36 hours, evolving without sequelae<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. </p>
      <p>The present study described a new case of liver failure in term neonate after repeated
doses of paracetamol, treated successfully with N-acetylcysteine. </p>
    </sec>
    <sec>
      <title>Case description</title>
      <p>Male patient, 26 days old, weighing 3,125g, son of non-consanguineous parents, sent by
the local emergency unit where he remained hospitalized for 24 hours with a history of
irritability, refusal to eat for 4 days, frequent vomiting for 1 day, abdominal
distension and slight respiratory distress. The delivery (iterative cesarean section)
was uneventful, and the neonate presented birth weight of 3,160g, 48cm, Apgar score 8
and 10 (1st and 5th minutes), and Capurro score of 39 weeks and 3 days. The mother, 38
years old, had 10 previous pregnancies (two cesareans), was confined in a penitentiary
since the 5th month of pregnancy and had a history of losing custody of nine children
due to negligence associated with addiction (crack). </p>
      <p>Before admission, the child was exclusively breastfed, on maternal care in a rooming in
prison. The mother reported having administered paracetamol orally (10mg/kg/dose every 4
hours for 3 consecutive days - total dose of approximately 180mg/kg, according to
previous prescription to another son), claiming that, a week ago the child was weepy and
"feverish". She also reported the concomitant use of paracetamol for 5 days for relief
of toothache (doses and frequency of use were not obtained). </p>
      <p>At admission (D1), the child was afebrile with signs of shock (heart rate - HR=183bpm,
slow capillary refill, weak pulse, inaudible blood pressure and mottled skin), jaundice,
hepatomegaly and massive upper gastrointestinal bleeding. The main laboratory findings
obtained in the first 24 hours of admission included coagulopathy (incoagulable
international normalized ratio - INR, activated partial thromboplastin time - APTT, and
thrombin time - TT), metabolic acidosis (pH 7,21; bicarbonate 7,1mEq/L; lactate
4,3mmol/L), hypoglycemia (18mg/dL), AST - 4,039UI/L, ALT - 1,087UI/L and
hyperbilirubinemia (total bilirubin - 9.57mg/dL; direct - 6.18mg/dL). During
hospitalization, there was a progressive fall in hemoglobin levels: D1 - 10.6g/dL; 3rd
day of hospitalization (D3) - 8.0g/dL. Serum concentration of paracetamol (approximately
36-48 hours after the last dose) was of 77&#xB5;g/mL (therapeutic range of 10-20&#xB5;g/mL,
spectrophotometric method). Considering the possibility of consumption by the mother and
passage through breast milk, a screening of recreational drugs (cocaine, cannabinoids,
methamphetamine and amphetamine) was performed by an immunochromatographic test in the
patient's urine, with negative results. Blood cultures collected on admission were also
negative. </p>
      <p>Supportive measures included: volume replacement, correction of hypoglycaemia, serial
transfusions of fresh frozen plasma, dobutamine, mechanical ventilation, empirical
antibiotic therapy (ampicillin and amikacin in D1-D3, while waiting for completion of
infectious screening), and transfusion of red blood cells (D3). After laboratory
confirmation of toxic exposure to paracetamol, the protocol of continuous intravenous
infusion of N-acetylcysteine in 21 hours was introduced (150mg/kg in 60 minutes; 50mg/kg
in 4 hours; 100mg/kg in 16 hours)<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>, maintained at 6.25mg/kg/hour until D11. Given the severity of the case and
the possibility of progression to liver transplantation, the patient was transferred to
the regional referral unit at D3, where he stayed for 19 days. During evolution, there
was a progressive decrease of aminotransferase concentrations and improvement of
coagulation; infusion of N-acetylcysteine was suspended on D11. The patient developed
hospital infection by oxacillin-resistant <italic>Staphylococcus aureus</italic> (D20),
treated with vancomycin. In <xref ref-type="table" rid="t01">Table 1</xref> are
summarized the main laboratory results achieved during the 34 days of hospitalization. </p>
      <p>
<table-wrap id="t01" orientation="portrait" position="float"><label>Table 1</label><caption><title> Main laboratory findings during hospitalization</title></caption><graphic xlink:href="0103-0582-rpp-32-01-00144-gt01"/></table-wrap>
</p>
      <p>In the screening of metabolic diseases that may present with liver failure in the
neonatal period, the analysis of the acylcarnitine profile in D2 showed reduced free
serum carnitine (5.03mol/L; reference values: 17.8-51.8mol/L), with values within the
normal range both in the material obtained in newborn screening tests and in dosages
performed after resolution of the clinical condition (D30 and D180). Research for
galactosemia, tyrosinemia, and organic acidemia was negative. Prenatal serological
testing for HIV, toxoplasmosis, syphilis, and hepatitis B and C were also negative. The
outpatient follow-up undertaken for one year showed complete clinical and laboratory
recovery and adequate neuropsychomotor development. </p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>In general, the time of peak absorption following ingestion of paracetamol is rapid
(30-45 minutes), with analgesic and antipyretic action achieved with serum
concentrations of 10 and 4-18&#xCE;1/4g/mL, respectively, including in children. About 90% of
paracetamol is conjugated in the liver (glucuronidation - 40-67%; sulfation - 20-46%),
forming inactive metabolites excreted in the urine. Approximately 5-15% of the drug is
oxidized in the CYP2E1 and, to a lesser extent in the CYP2A6, CYP1A2, and CYP3A4,
resulting in the formation of toxic metabolite N-acetyl-p-benzoquinone imine (NAPQI),
which readily combines with glutathione, turning into nontoxic cysteine/mercaptate
conjugates eliminated in urine. The hepatotoxic action of paracetamol is associated
primarily to the activity of the CYP2E1 enzyme system and the production of
NAPQI<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. In overdoses with clinical repercussion, by isolated overdoses or after
supratherapeutic doses, the maximum rates of glucuronidation and sulfation are reached
and the availability of glutathione is insufficient to metabolize NAPQI. Then, the free
NAPQI binds covalently to hepatic proteins of the cysteine group, triggering
hepatotoxicity and cell death<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. Acetaminophen-protein products, such as
3-(cysteine-S-yl)-paracetamol-adduct are released into the blood after hepatocyte lysis.
They are measured by high performance liquid chromatography with electrochemical
detection and may be used as specific biomarkers of hepatotoxicity, even several days
after the exposure<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. A study in adults who developed liver failure induced by paracetamol
overdoses showed a positive correlation between the serum concentration of
acetaminophen-protein adducts and severity of hepatotoxicity, which can be detected up
to 12 days after ingestion<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. </p>
      <p>In contrast, the pharmacokinetics and pharmacodynamics of paracetamol in neonates and
young infants (under 1 year) differ substantially from older children and adults. The
combination with glucuronides is immature, while sulfation is well developed, consisting
in the main metabolic pathway<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. The clearance of paracetamol in term neonates is decreased and the
half-life is prolonged compared to that of adults (approximately 3.5
<italic>versus</italic> 1.9-2.2 hours), so a distinct dosage is recommended
(20mg/kg/dose, every 8 hours, no longer than 48 hours of use), due to the risk of
toxicity of cumulative doses<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. In addition, the elimination half-life of paracetamol may be extended
further after multiple doses, in poisoned patients and in those who develop liver
failure<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>.Although the rates of metabolism of CYP2E1 were decreased and the ability
to generate glutathione, increased, providing greater protection after isolated
overdoses, neonates may also produce toxic metabolites (NAPQI)<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>, triggering up hepatotoxicity and cell lysis if glutathione reserves are
depleted<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. It should be noted that paracetamol-protein products could also be used as
specific biomarkers of hepatotoxicity in children, especially to assist the diagnosis of
acute liver failure of unknown etiology<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>. </p>
      <p>Even considering the background of the mother, which could raise doubts about the actual
dose, the continuous use of medication for 3 days, the possible additional doses
transferred through breast milk, and the high serum paracetamol levels detected
established a causal relationship between prolonged use drug and liver failure.
Reinforcing these findings, Penna and Buchanan described in their review the cases of
two young infants, 6 to 7 weeks of life, who also developed severe hepatotoxicity after
ingesting repeated doses of paracetamol (approximately 100mg/kg/day/2 days and
60mg/kg/day/6 days, respectively)<sup>(</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>. </p>
      <p>N-acetylcysteine is the antidote of choice in the treatment of acetaminophen poisoning,
being a precursor of reduced glutathione, which, when given early, can prevent liver
damage induced by paracetamol, restoring glutathione levels<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. When the moment of exposure is known, the administration of
N-acetylcysteine is formally indicated after ingestion of isolated overdoses of
paracetamol, when the serum levels, preferably obtained between 4 and 8 hours of
ingestion are above the possible risk line on the Rumack-Matthew nomogram, even without
clinical or laboratory evidence of liver injury<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. When the time of exposure is unknown or it is not possible to get the
serum concentration levels within 8 hours of exposure, but the estimated dose is above
200mg/kg in the last 24 hours (or &#x2265;10g in adolescents and adults), the use of
N-acetylcysteine is also indicated, and the decision about the suspension of treatment
is based on clinical and laboratory progress<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>,</sup>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup>. </p>
      <p>Other more complex situations involve the indication of N-acetylcysteine after prolonged
or supratherapeutic use of paracetamol, when assessing the risk of hepatotoxicity by the
Rumack-Matthew nomogram is not possible<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>-</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. In general, it is recommended the use of N-acetylcysteine when the serum
concentration of paracetamol is above 10&#xB5;g/mL or AST&gt;50UI/L<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. In patients with liver failure, as described, N-acetylcysteine also
possibly acts as an antioxidant, improving hemodynamics, oxygen consumption, and
cerebral edema<sup>(</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. Patients with paracetamol-induced liver failure, either by isolated
overdoses or by supratherapeutic doses, should be given intravenous N-acetylcysteine
until the encephalopathy resolves itself or until they present significant improvements
in the results of ALT, INR, and creatinine or until liver transplantation<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. In the present case, continuous intravenous infusion of N-acetylcysteine
proved to be effective, safe, and without adverse effects, even in prolonged use. </p>
      <p>Although studies in experimental models suggest that carnitine deficiency, as a cause or
consequence, may be associated with hepatotoxicity triggered by
acetaminophen<sup>(</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup>, it would be speculative to infer this association only with the data
available in the present report (a single measurement during the course of liver
failure). Clinical studies are needed to define and characterize the association more
accurately. However, it can be inferred that the laboratory screening, the evolution,
and the outpatient follow-up practically exclude the possibility of genetic diseases
associated with changes in the carnitine transport and the carnitine cycle, which can
evolve with liver failure<sup>(</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup>. </p>
      <p>It is possible to conclude that the continued use of acetaminophen can cause severe
hepatotoxicity in neonates. The specific dosage for term and preterm neonates should be
followed, avoiding the continuous use for more than 2 to 3 days<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. </p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="other">
        <p>Institui&#xE7;&#xE3;o: Faculdade de Ci&#xEA;ncias M&#xE9;dicas da Universidade Estadual de Campinas
(Unicamp), Campinas, SP, Brasil</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References </title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lederman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Fysh</surname>
              <given-names>WJ</given-names>
            </name>
            <name>
              <surname>Tredger</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gamsu</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Neonatal paracetamol poisoning: treatment by exchange
transfusion</article-title>
          <source>Arch Dis Child</source>
          <year>1983</year>
          <volume>58</volume>
          <fpage>631</fpage>
          <lpage>633</lpage>
          <pub-id pub-id-type="pmid">6614980</pub-id>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Roberts</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Robinson</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Mughal</surname>
              <given-names>MZ</given-names>
            </name>
            <name>
              <surname>Ratcliffe</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Prescott</surname>
              <given-names>LF</given-names>
            </name>
          </person-group>
          <article-title>Paracetamol metabolites in the neonate following
maternal overdose</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>1984</year>
          <volume>18</volume>
          <fpage>201</fpage>
          <lpage>206</lpage>
          <pub-id pub-id-type="pmid">6487458</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>AW</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Dhawan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Mieli-Vergani</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Neonatal paracetamol poisoning</article-title>
          <source>Arch Dis Child Fetal Neonatal Ed</source>
          <year>1999</year>
          <volume>81</volume>
          <fpage>F78</fpage>
          <lpage>F78</lpage>
          <pub-id pub-id-type="pmid">10744435</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Isbister</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Bucens</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Whyte</surname>
              <given-names>IM</given-names>
            </name>
          </person-group>
          <article-title>Paracetamol overdose in a preterm
neonate</article-title>
          <source>Arch Dis Child Fetal Neonatal Ed</source>
          <year>2001</year>
          <volume>85</volume>
          <fpage>F70</fpage>
          <lpage>F72</lpage>
          <pub-id pub-id-type="pmid">11420329</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>De la Pinti&#xE9;re</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Beuch&#xE9;e</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>B&#xE9;tr&#xE9;mieux</surname>
              <given-names>PE</given-names>
            </name>
          </person-group>
          <article-title>Intravenous propacetamol overdose in a term
newborn</article-title>
          <source>Arch Dis Child Fetal Neonatal Ed</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>F351</fpage>
          <lpage>F352</lpage>
          <pub-id pub-id-type="pmid">12819181</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nevin</surname>
              <given-names>DG</given-names>
            </name>
            <name>
              <surname>Shung</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>Intravenous paracetamol overdose in a preterm infant
during anesthesia</article-title>
          <source>Paediatr Anaesth</source>
          <year>2010</year>
          <volume>20</volume>
          <fpage>105</fpage>
          <lpage>107</lpage>
          <pub-id pub-id-type="pmid">20078803</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Walls</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Baker</surname>
              <given-names>CF</given-names>
            </name>
            <name>
              <surname>Sarkar</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Acetaminophen-induced hepatic failure with
encephalopathy in a newborn</article-title>
          <source>J Perinatol</source>
          <year>2007</year>
          <volume>27</volume>
          <fpage>133</fpage>
          <lpage>135</lpage>
          <pub-id pub-id-type="pmid">17262050</pub-id>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>McKiernan</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Etiology, outcome and prognostic indicators of childhood
fulminant hepatic failure in the United Kingdom</article-title>
          <source>J Pediatr Gastroenterol Nutr</source>
          <year>2005</year>
          <volume>40</volume>
          <fpage>575</fpage>
          <lpage>581</lpage>
          <pub-id pub-id-type="pmid">15861019</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahadevan</surname>
              <given-names>SB</given-names>
            </name>
            <name>
              <surname>McKiernan</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Davies</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kelly</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Paracetamol induced hepatotoxicity</article-title>
          <source>Arch Dis Child</source>
          <year>2006</year>
          <volume>91</volume>
          <fpage>598</fpage>
          <lpage>603</lpage>
          <pub-id pub-id-type="pmid">16547087</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arana</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Morton</surname>
              <given-names>NS</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>TG</given-names>
            </name>
          </person-group>
          <article-title>Treatment with paracetamol in infants</article-title>
          <source>Acta Anaesthesiol Scand</source>
          <year>2001</year>
          <volume>45</volume>
          <fpage>20</fpage>
          <lpage>29</lpage>
          <pub-id pub-id-type="pmid">11152028</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Howland</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hendrickson</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <chapter-title>Antidotes in depth. N-acetylcysteine</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Nelson</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Lewin</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Howland</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Goldfrank</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Flomenbaum</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <source>Goldfrank's toxicologic emergencies</source>
          <edition>9th ed</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill</publisher-name>
          <fpage>500</fpage>
          <lpage>507</lpage>
          <year>2011</year>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hendrickson</surname>
              <given-names>RG</given-names>
            </name>
          </person-group>
          <chapter-title>Acetaminophen</chapter-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Nelson</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Lewin</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Howland</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Hoffman</surname>
              <given-names>RS</given-names>
            </name>
            <name>
              <surname>Goldfrank</surname>
              <given-names>LR</given-names>
            </name>
            <name>
              <surname>Flomenbaum</surname>
              <given-names>NE</given-names>
            </name>
          </person-group>
          <source>Goldfrank's toxicologic emergencies</source>
          <edition>9</edition>
          <publisher-loc>New York</publisher-loc>
          <publisher-name>McGraw-Hill</publisher-name>
          <fpage>483</fpage>
          <lpage>499</lpage>
          <year>2011</year>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Letzig</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Simpson</surname>
              <given-names>PM</given-names>
            </name>
            <name>
              <surname>Capparelli</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Roberts</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Hinson</surname>
              <given-names>JA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pharmacokinetics of acetaminophen-protein adducts in
adults with acetaminophen overdose and acute liver failure</article-title>
          <source>Drug Metab Dispos</source>
          <year>2009</year>
          <volume>37</volume>
          <fpage>1779</fpage>
          <lpage>1784</lpage>
          <pub-id pub-id-type="pmid">19439490</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Anderson</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>van Lingen</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Hansen</surname>
              <given-names>TG</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>YC</given-names>
            </name>
            <name>
              <surname>Holford</surname>
              <given-names>NH</given-names>
            </name>
          </person-group>
          <article-title>Acetaminophen developmental pharmacokinetics in
premature neonates and infants: a pooled population analysis</article-title>
          <source>Anesthesiology</source>
          <year>2002</year>
          <volume>96</volume>
          <fpage>1336</fpage>
          <lpage>1345</lpage>
          <pub-id pub-id-type="pmid">12170045</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>James</surname>
              <given-names>LP</given-names>
            </name>
            <name>
              <surname>Alonso</surname>
              <given-names>EM</given-names>
            </name>
            <name>
              <surname>Hynan</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Hinson</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Davern</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>WM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detection of acetaminophen protein adducts in children
with acute liver failure of indeterminate cause</article-title>
          <source>Pediatrics</source>
          <year>2006</year>
          <volume>118</volume>
          <fpage>e676</fpage>
          <lpage>e681</lpage>
          <pub-id pub-id-type="pmid">16950959</pub-id>
        </element-citation>
      </ref>
      <ref id="B16">
        <label>16</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Penna</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Buchanan</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Paracetamol poisoning in children and
hepatotoxicity</article-title>
          <source>Br J Clin Pharmacol</source>
          <year>1991</year>
          <volume>32</volume>
          <fpage>143</fpage>
          <lpage>149</lpage>
          <pub-id pub-id-type="pmid">1931463</pub-id>
        </element-citation>
      </ref>
      <ref id="B17">
        <label>17</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heard</surname>
              <given-names>KJ</given-names>
            </name>
          </person-group>
          <article-title>Acetylcysteine for acetaminophen
poisoning</article-title>
          <source>N Engl J Med</source>
          <year>2008</year>
          <volume>359</volume>
          <fpage>285</fpage>
          <lpage>292</lpage>
          <pub-id pub-id-type="pmid">18635433</pub-id>
        </element-citation>
      </ref>
      <ref id="B18">
        <label>18</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dart</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Erdman</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Olson</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Christianson</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Manoguerra</surname>
              <given-names>AS</given-names>
            </name>
            <name>
              <surname>Chyka</surname>
              <given-names>PA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Acetaminophen poisoning: an evidence-based consensus
guideline for out-of-hospital management</article-title>
          <source>Clin Toxicol (Phila)</source>
          <year>2006</year>
          <volume>44</volume>
          <fpage>1</fpage>
          <lpage>18</lpage>
        </element-citation>
      </ref>
      <ref id="B19">
        <label>19</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Daly</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>O'Malley</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Heard</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Bogdan</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Dart</surname>
              <given-names>RC</given-names>
            </name>
          </person-group>
          <article-title>Prospective evaluation of repeated supratherapeutic
acetaminophen (paracetamol) ingestion</article-title>
          <source>Ann Emerg Med</source>
          <year>2004</year>
          <volume>44</volume>
          <fpage>393</fpage>
          <lpage>398</lpage>
          <pub-id pub-id-type="pmid">15459622</pub-id>
        </element-citation>
      </ref>
      <ref id="B20">
        <label>20</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Arafa</surname>
              <given-names>HM</given-names>
            </name>
          </person-group>
          <article-title>Carnitine deficiency: a possible risk factor in
paracetamol hepatotoxicity</article-title>
          <source>Arch Toxicol</source>
          <year>2009</year>
          <volume>83</volume>
          <fpage>139</fpage>
          <lpage>150</lpage>
          <pub-id pub-id-type="pmid">18597074</pub-id>
        </element-citation>
      </ref>
      <ref id="B21">
        <label>21</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Longo</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Amat di San Filippo</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Pasquali</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Disorders of carnitine transport and the carnitine
cycle</article-title>
          <source>Am J Med Genet C Semin Med Genet</source>
          <year>2006</year>
          <volume>142C</volume>
          <fpage>77</fpage>
          <lpage>85</lpage>
          <pub-id pub-id-type="pmid">16602102</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Fal&#xEA;ncia hep&#xE1;tica aguda em neonato de termo ap&#xF3;s ingest&#xE3;o de doses
repetidas de paracetamol </article-title>
      </title-group>
      <abstract>
        <sec>
          <title>Objetivo:</title>
          <p> A hepatoxicidade grave induzida pelo paracetamol &#xE9; muito rara em neonatos.
Relata-se o caso de um neonato de termo que desenvolveu fal&#xEA;ncia hep&#xE1;tica aguda
ap&#xF3;s o uso de paracetamol. </p>
        </sec>
        <sec>
          <title>Descri&#xE7;&#xE3;o do caso:</title>
          <p> Menino, 26 dias, admitido com sangramento intestinal, sinais de choque, discreta
hepatomegalia, coagulopatia, acidose metab&#xF3;lica (pH=7,21; bicarbonato: 7,1mEq/L),
hipoglicemia (18mg/dL), aumento das aminotransferases s&#xE9;ricas (AST=4.039UI/L;
ALT=1.087UI/L) e hiperbilirrubinemia (total: 9,57mg/dL; direta: 6,18mg/dL), ap&#xF3;s
uso de paracetamol via oral (10mg/kg/dose a cada quatro horas) por tr&#xEA;s dias
consecutivos (dose total ao redor de 180mg/kg; n&#xED;vel s&#xE9;rico de 36-48 horas ap&#xF3;s a
&#xFA;ltima dose de 77&#xB5;g/mL). Al&#xE9;m das medidas de suporte, o paciente foi tratado com
N-acetilciste&#xED;na (infus&#xE3;o intravenosa cont&#xED;nua por 11 dias consecutivos),
recebendo alta ap&#xF3;s 34 dias de interna&#xE7;&#xE3;o. O seguimento mostrou recupera&#xE7;&#xE3;o
cl&#xED;nica e dos par&#xE2;metros laboratoriais da fun&#xE7;&#xE3;o hep&#xE1;tica. </p>
        </sec>
        <sec>
          <title>Coment&#xE1;rios:</title>
          <p> A farmacocin&#xE9;tica e a farmacodin&#xE2;mica do paracetamol em neonatos e lactentes
jovens (menores de um ano) diferem substancialmente de crian&#xE7;as maiores e adultos.
Apesar de as taxas de metabolismo do sistema enzim&#xE1;tico P-450 CYP2E1 estarem
diminu&#xED;das e a capacidade de gerar glutationa, aumentadas - conferindo maior
prote&#xE7;&#xE3;o ap&#xF3;s superdosagens -, existe a possibilidade de produ&#xE7;&#xE3;o de metab&#xF3;litos
hepatot&#xF3;xicos (N-acetil-p-benzoquinoneimina) que determinam lise celular, caso se
esgotem as reservas de glutationa. A depura&#xE7;&#xE3;o &#xE9; diminu&#xED;da e a meia-vida de
elimina&#xE7;&#xE3;o &#xE9; prolongada, recomendando-se posologia distinta pelo risco de
toxicidade de doses cumulativas. O presente relato destaca o risco de
hepatotoxicidade grave em neonatos ap&#xF3;s o uso cont&#xED;nuo de paracetamol por mais de
dois a tr&#xEA;s dias.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="pt">
        <kwd>acetaminofen</kwd>
        <kwd>fal&#xEA;ncia hep&#xE1;tica</kwd>
        <kwd>rec&#xE9;m-nascido</kwd>
        <kwd>N-acetilciste&#xED;na</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>O paracetamol (N-acetil-p-aminofenol) &#xE9; um analg&#xE9;sico e antipir&#xE9;tico amplamente
utilizado em crian&#xE7;as, sendo raras as exposi&#xE7;&#xF5;es t&#xF3;xicas em neonatos. As exposi&#xE7;&#xF5;es
t&#xF3;xicas podem ocorrer por via transplacent&#xE1;ria, decorrentes de ingest&#xF5;es intencionais
de overdoses de paracetamol por m&#xE3;es nas 24 horas que precedem o parto<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>-</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup>, devido a erros de dosagem isolada oral<sup>(4) </sup>ou intravenosa
(propacetamol, pr&#xF3;-f&#xE1;rmaco do paracetamol e n&#xE3;o dispon&#xED;vel no Brasil)<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>, em geral, na ordem de dez vezes a dose terap&#xEA;utica, ou devido a doses
repetidas por via oral<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. </p>
        <p>A hepatoxicidade grave induzida pelo paracetamol, com ou sem fal&#xEA;ncia hep&#xE1;tica aguda,
praticamente n&#xE3;o &#xE9; descrita no per&#xED;odo neonatal. Em uma revis&#xE3;o de 97 casos de
fal&#xEA;ncia hep&#xE1;tica aguda em pacientes com idade &lt;17 anos, em duas unidades
regionais de refer&#xEA;ncia de transplante hep&#xE1;tico em Pediatria no Reino Unido
(1991-2000), n&#xE3;o houve casos de fal&#xEA;ncia hep&#xE1;tica por medicamentos no grupo neonatal
(n=17; doen&#xE7;as metab&#xF3;licas - dez casos; doen&#xE7;as infecciosas - sete casos). No
entanto, o paracetamol foi o principal medicamento associado &#xE0; fal&#xEA;ncia hep&#xE1;tica (14
em 19 casos), principalmente no grupo et&#xE1;rio maior de cinco anos (n=11), resultando
em sete &#xF3;bitos<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup>. Outro estudo analisou uma s&#xE9;rie de 51 crian&#xE7;as e adolescentes que
evolu&#xED;ram com hepatotoxicidade induzida por paracetamol (45 por overdose isolada e
seis por doses repetidas e cumulativas), todos com n&#xED;veis s&#xE9;ricos de aspartato
aminotransferase (AST) ou alanino aminotransferase (ALT) &gt;1.000UI/L, sendo que 11
evolu&#xED;ram com fal&#xEA;ncia hep&#xE1;tica (encefalopatia e/ou coagulopatia). Destes, seis foram
submetidos a transplante hep&#xE1;tico - dois sobreviveram - e os outros cinco que
aguardavam o transplante faleceram. O paciente mais jovem dessa s&#xE9;rie tinha dez meses
de idade<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup>. </p>
        <p>Em extensa revis&#xE3;o efetuada por Arana <italic>et al</italic>, referente ao per&#xED;odo de
1978 a 2001, nenhum caso de intoxica&#xE7;&#xE3;o por paracetamol por administra&#xE7;&#xE3;o direta em
neonatos havia sido relatado<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>. Em 2007, Walls <italic>et al </italic>descreveram o primeiro caso de
fal&#xEA;ncia hep&#xE1;tica em um neonato de termo com quatro dias de vida ap&#xF3;s o uso de
paracetamol via oral por tr&#xEA;s dias consecutivos (peso de 3,1kg; 26mg/kg/dose a cada
quatro horas no primeiro dia; 13mg/kg/dose a cada quatro horas no segundo e terceiro
dias; dose total acumulada de aproximadamente 312mg/kg), prescrito como analg&#xE9;sico no
p&#xF3;s-operat&#xF3;rio de uma postectomia realizada no primeiro dia de vida, detectando-se
n&#xED;vel s&#xE9;rico de paracetamol de 109,8&#xB5;g/mL, 16 horas ap&#xF3;s a &#xFA;ltima dose administrada.
O paciente apresentou recupera&#xE7;&#xE3;o completa ap&#xF3;s infus&#xE3;o cont&#xED;nua intravenosa de
N-acetilciste&#xED;na por 36 horas, evoluindo sem sequelas<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup>. </p>
        <p>Neste trabalho, descreveu-se um novo caso de fal&#xEA;ncia hep&#xE1;tica em neonato de termo
ap&#xF3;s ingest&#xE3;o de doses repetidas de paracetamol, tratado de forma bem sucedida com
N-acetilciste&#xED;na. </p>
      </sec>
      <sec>
        <title>Descri&#xE7;&#xE3;o do caso</title>
        <p>Menino com 26 dias de vida, pesando 3125g, filho de pais n&#xE3;o consangu&#xED;neos,
encaminhado da unidade de emerg&#xEA;ncia local onde permanecera internado por 24 horas
com hist&#xF3;ria de irritabilidade, recusa alimentar havia quatro dias, v&#xF4;mitos
frequentes havia um dia, distens&#xE3;o abdominal e desconforto respirat&#xF3;rio leve. O parto
(ces&#xE1;rea por iteratividade) foi sem intercorr&#xEA;ncias, com o rec&#xE9;m-nascido pesando
3160g, medindo 48cm, apresentando Boletim de Apgar 8 e 10 (1&#xBA; e 5&#xBA; minutos) e exame
f&#xED;sico compat&#xED;vel com de 39 semanas e tr&#xEA;s dias. A m&#xE3;e, de 38 anos, apresentava
antecedente de dez gesta&#xE7;&#xF5;es (duas ces&#xE1;reas), reclus&#xE3;o em penitenci&#xE1;ria desde o
quinto m&#xEA;s de gesta&#xE7;&#xE3;o e antecedente de perda de guarda dos nove filhos vivos por
neglig&#xEA;ncia associada &#xE0; depend&#xEA;ncia qu&#xED;mica (<italic>crack</italic>). Antes da
interna&#xE7;&#xE3;o, a crian&#xE7;a estava em aleitamento exclusivo, sob cuidado materno em um
alojamento conjunto no pres&#xED;dio. A m&#xE3;e referiu ter administrado paracetamol por via
oral (10mg/kg/dose a cada quatro horas por tr&#xEA;s dias consecutivos - dose total
aproximada de 180mg/kg, seguindo antiga prescri&#xE7;&#xE3;o m&#xE9;dica para outro filho), alegando
que, havia uma semana, a crian&#xE7;a estava chorosa e "febril". Relatou tamb&#xE9;m o uso
concomitante de paracetamol durante cinco dias para al&#xED;vio de odontalgia (doses e
frequ&#xEA;ncia de uso n&#xE3;o obtidas). </p>
        <p>&#xC0; admiss&#xE3;o (D1), a crian&#xE7;a estava afebril, com sinais de choque (frequ&#xEA;ncia card&#xED;aca
- FC=183bpm, enchimento capilar lento, pulsos finos, press&#xE3;o arterial inaud&#xED;vel e
rendilhado cut&#xE2;neo), icter&#xED;cia, hepatomegalia e sangramento digestivo alto volumoso.
Os principais achados laboratoriais obtidos nas primeiras 24 horas de interna&#xE7;&#xE3;o
inclu&#xED;ram coagulopatia (raz&#xE3;o normalizada internacional - RNI, tempo de
tromboplastina parcial ativado - TTPA e tempo de trombina - TT incoagul&#xE1;veis),
acidose metab&#xF3;lica (pH 7,21; bicarbonato 7,1mEq/L; lactato 4,3mmol/L), hipoglicemia
(18mg/dL), AST - 4.039UI/L, ALT - 1.087UI/L e hiperbilirrubinemia (bilirrubina total
- 9,57mg/dL; direta - 6,18mg/dL). Durante a interna&#xE7;&#xE3;o, houve queda progressiva dos
n&#xED;veis de hemoglobina: D1 - 10,6g/dL; terceiro dia de interna&#xE7;&#xE3;o (D3) - 8,0g/dL. A
concentra&#xE7;&#xE3;o s&#xE9;rica de paracetamol (aproximadamente 36-48 horas ap&#xF3;s a &#xFA;ltima dose
administrada) foi de 77&#xB5;g/mL (faixa terap&#xEA;utica de 10-20&#xB5;g/mL, m&#xE9;todo
espectrofotom&#xE9;trico). Considerando a possibilidade de con-sumo pela m&#xE3;e e a passagem
pelo leite materno, realizou-se a triagem de drogas recreativas (coca&#xED;na,
canabinoides, metanfetamina e anfetaminas) por imunocromatografia na urina do
paciente, com resultado negativo. As hemoculturas coletadas &#xE0; admiss&#xE3;o tamb&#xE9;m foram
negativas. </p>
        <p>As medidas de suporte inclu&#xED;ram reposi&#xE7;&#xE3;o vol&#xEA;mica, corre&#xE7;&#xE3;o da hipoglicemia,
transfus&#xF5;es seriadas de plasma fresco congelado, dobutamina, ventila&#xE7;&#xE3;o mec&#xE2;nica,
antibioticoterapia emp&#xED;rica (ampicilina e amicacina em D1-D3, enquanto se aguardava
finaliza&#xE7;&#xE3;o da triagem infecciosa) e transfus&#xE3;o de concentrado de hem&#xE1;cias (D3). Ap&#xF3;s
a confirma&#xE7;&#xE3;o laboratorial da exposi&#xE7;&#xE3;o t&#xF3;xica ao paracetamol, iniciou-se o protocolo
de infus&#xE3;o intravenosa cont&#xED;nua de N-acetilciste&#xED;na em 21 horas (150mg/kg em 60
minutos; 50mg/kg em quatro horas; 100mg/kg em 16 horas)<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup>, mantida em 6,25mg/kg/hora at&#xE9; o D11. Diante da gravidade do caso e da
possibilidade de evolu&#xE7;&#xE3;o para transplante hep&#xE1;tico, transferiu-se o paciente para a
unidade de refer&#xEA;ncia regional no D3, onde ficou por 19 dias. Durante a evolu&#xE7;&#xE3;o,
houve queda progressiva das aminotransferases e melhora da coagula&#xE7;&#xE3;o, suspendendo-se
a infus&#xE3;o de N-acetilciste&#xED;na no D11. Como complica&#xE7;&#xE3;o, desenvolveu infec&#xE7;&#xE3;o
hospitalar por <italic>Staphylococcus aureus </italic>resistente &#xE0; oxacilina (D20),
tratada com vancomicina. Na <xref ref-type="table" rid="t02">Tabela 1</xref>, est&#xE3;o
sumarizados os principais resultados laboratoriais realizados durante os 34 dias de
interna&#xE7;&#xE3;o. </p>
        <p>
<table-wrap id="t02" orientation="portrait" position="float"><label>Tabela 1</label><caption><title> Principais achados laboratoriais durante a interna&#xE7;&#xE3;o</title></caption><graphic xlink:href="0103-0582-rpp-32-01-00144-gt01-pt"/></table-wrap>
</p>
        <p>Na triagem de doen&#xE7;as metab&#xF3;licas que podem cursar com fal&#xEA;ncia hep&#xE1;tica no per&#xED;odo
neonatal, a an&#xE1;lise do perfil de acilcarnitinas em D2 evidenciou redu&#xE7;&#xE3;o da carnitina
livre s&#xE9;rica (5,03mol/L; valores de refer&#xEA;ncia: 17,8-51,8mol/L), com valores dentro
da normalidade tanto em material obtido no teste de triagem neonatal quanto em
dosagens realizadas ap&#xF3;s resolu&#xE7;&#xE3;o do quadro (D30 e D180). A investiga&#xE7;&#xE3;o para
galactosemia, tirosinemia e acidemia org&#xE2;nica foi negativa. Os exames sorol&#xF3;gicos
pr&#xE9;-natais para a pesquisa de HIV, toxoplasmose, s&#xED;filis, hepatite B e C tamb&#xE9;m foram
negativos. O seguimento ambulatorial realizado durante um ano revelou completa
recupera&#xE7;&#xE3;o cl&#xED;nica-laboratorial e desenvolvimento neuropsicomotor adequado. </p>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>De maneira geral, o tempo de pico da absor&#xE7;&#xE3;o do paracetamol ap&#xF3;s a ingest&#xE3;o &#xE9; r&#xE1;pido
(30-45 minutos), com a&#xE7;&#xE3;o analg&#xE9;sica e antipir&#xE9;tica atingida com concentra&#xE7;&#xF5;es
s&#xE9;ricas de 10 e de 4-18&#xCE;1/4g/mL, respectivamente, inclusive em crian&#xE7;as. Cerca de 90%
do paracetamol &#xE9; conjugado no f&#xED;gado (glucorinida&#xE7;&#xE3;o - 40-67%; sulfata&#xE7;&#xE3;o - 20-46%),
formando-se metab&#xF3;litos inativos eliminados na urina. Aproximadamente 5-15% do
medicamento &#xE9; oxidado no CYP2E1 e, em menor extens&#xE3;o, no CYP2A6, no CYP1A2 e no
CYP3A4, resultando na forma&#xE7;&#xE3;o do metab&#xF3;lito t&#xF3;xico N-acetil-p-benzoquinoneimina
(NAPQUI), que rapidamente se combina com a glutationa, transformando-se em conjugados
de ciste&#xED;na e mercaptatos n&#xE3;o t&#xF3;xicos eliminados na urina. A a&#xE7;&#xE3;o hepatot&#xF3;xica do
paracetamol associa-se basicamente &#xE0; atividade do sistema enzim&#xE1;tico CYP2E1 e &#xE0;
produ&#xE7;&#xE3;o do NAPQUI<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. Em superdosagens com repercuss&#xE3;o cl&#xED;nica, por overdoses isoladas ou
ap&#xF3;s doses supraterap&#xEA;uticas, as taxas m&#xE1;ximas de glucorinida&#xE7;&#xE3;o e de sulfata&#xE7;&#xE3;o s&#xE3;o
atingidas e a disponibilidade de glutationa &#xE9; insuficiente para metabolizar o NAPQUI.
Em seguida, o NAPQUI livre liga-se covalentemente &#xE0;s prote&#xED;nas hep&#xE1;ticas do grupo
ciste&#xED;na, desencadeando hepatotoxicidade e morte celular<sup>(</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. Produtos de prote&#xED;na-paracetamol, como a
3-(ciste&#xED;na-S-yl)-paracetamol-aduto, s&#xE3;o liberados no sangue ap&#xF3;s a lise do
hepat&#xF3;cito. S&#xE3;o mensur&#xE1;veis por cromatografia l&#xED;quida de alta efici&#xEA;ncia com detec&#xE7;&#xE3;o
eletroqu&#xED;mica, podendo ser usados como biomarcadores espec&#xED;ficos de hepatotoxicidade,
mesmo com v&#xE1;rios dias ap&#xF3;s a exposi&#xE7;&#xE3;o<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. Estudo em adultos que evolu&#xED;ram com fal&#xEA;ncia hep&#xE1;tica induzida por
overdoses de paracetamol mostra correla&#xE7;&#xE3;o positiva entre a concentra&#xE7;&#xE3;o s&#xE9;rica dos
adutos de prote&#xED;na-paracetamol e a gravidade da hepatotoxicidade, podendo ser
detectada at&#xE9; 12 dias ap&#xF3;s a ingest&#xE3;o<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup>. </p>
        <p>Em contraste, a farmacocin&#xE9;tica e a farmacodin&#xE2;mica do paracetamol em neonatos e em
lactentes jovens (menores de um ano) diferem substancialmente de crian&#xE7;as maiores e
de adultos. A conjuga&#xE7;&#xE3;o com glucoron&#xED;deos &#xE9; imatura, enquanto a sulfata&#xE7;&#xE3;o &#xE9; bem
desenvolvida, consistindo na principal via de metaboliza&#xE7;&#xE3;o<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. A depura&#xE7;&#xE3;o do paracetamol em neonatos de termo &#xE9; diminu&#xED;da e a
meia-vida de elimina&#xE7;&#xE3;o &#xE9; prolongada quando comparada &#xE0; de adultos (aproximadamente
3,5 <italic>versus</italic> 1,9-2,2 horas), recomendando-se posologia distinta
(20mg/kg/dose, a cada oito horas, com m&#xE1;ximo de 48 horas de uso), pelo risco de
toxicidade de doses cumulativas<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. Al&#xE9;m disso, a meia-vida de elimina&#xE7;&#xE3;o do paracetamol pode se prolongar
ainda mais ap&#xF3;s m&#xFA;ltiplas doses, em pacientes intoxicados e nos que desenvolvem
fal&#xEA;ncia hep&#xE1;tica<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>.Apesar de as taxas de metabolismo do CYP2E1 estarem diminu&#xED;das e a
capacidade de gerar glutationa, aumentada, conferindo maior prote&#xE7;&#xE3;o ap&#xF3;s overdoses
isoladas, os neonatos tamb&#xE9;m podem produzir metab&#xF3;litos t&#xF3;xicos (NAPQUI)<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>, desencadeando-se hepatotoxicidade e lise celular, caso se esgotem as
reservas de glutationa<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. Cabe salientar que produtos de prote&#xED;na-paracetamol tamb&#xE9;m podem ser
usados como biomarcadores espec&#xED;ficos de hepatotoxicidade em crian&#xE7;as, principalmente
para auxiliar o diagn&#xF3;stico de fal&#xEA;ncia hep&#xE1;tica aguda de causa
indeterminada<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup>. </p>
        <p>Mesmo considerando-se os antecedentes da m&#xE3;e, que poderiam gerar d&#xFA;vidas sobre a real
dose administrada, o uso cont&#xED;nuo da medica&#xE7;&#xE3;o por tr&#xEA;s dias, as poss&#xED;veis doses
adicionais transferidas pelo leite materno e o alto n&#xED;vel s&#xE9;rico detectado de
paracetamol estabelecem nexo causal entre o uso prolongado da droga e a fal&#xEA;ncia
hep&#xE1;tica. Refor&#xE7;ando esses achados, Penna e Buchanan descreveram, em sua revis&#xE3;o, os
casos de dois lactentes jovens, de seis e sete semanas de vida, que tamb&#xE9;m
desenvolveram hepatotoxicidade grave ap&#xF3;s ingerirem doses repetidas de paracetamol
(aproximadamente 100mg/kg/dia/dois dias e 60mg/kg/dia/seis dias,
respectivamente)<sup>(</sup>
<xref rid="B16" ref-type="bibr">
<sup>16</sup>
</xref>
<sup>)</sup>. </p>
        <p>A N-acetilciste&#xED;na &#xE9; o ant&#xED;doto de elei&#xE7;&#xE3;o no tratamento das intoxica&#xE7;&#xF5;es por
paracetamol, sendo um precursor da glutationa reduzida que, ao ser administrada
precocemente, pode evitar a les&#xE3;o hep&#xE1;tica induzida pelo paracetamol, restaurando os
n&#xED;veis de glutationa<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. Quando se conhece o momento da exposi&#xE7;&#xE3;o, a administra&#xE7;&#xE3;o de
N-acetilciste&#xED;na est&#xE1; formalmente indicada ap&#xF3;s a ingest&#xE3;o de overdoses isoladas de
paracetamol, quando os n&#xED;veis s&#xE9;ricos, preferencialmente obtidos entre quatro e oito
horas da ingest&#xE3;o, est&#xE3;o acima da linha de risco de hepatotoxicidade no nomograma de
Rumack-Matthew, mesmo sem evid&#xEA;ncias cl&#xED;nicas ou laboratoriais de les&#xE3;o
hep&#xE1;tica<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup>. Quando se desconhece o momento da exposi&#xE7;&#xE3;o ou n&#xE3;o &#xE9; poss&#xED;vel obter a
concentra&#xE7;&#xE3;o s&#xE9;rica dentro de oito horas da exposi&#xE7;&#xE3;o, por&#xE9;m a dose estimada de
ingest&#xE3;o est&#xE1; acima de 200mg/kg nas &#xFA;ltimas 24 horas (ou &#x2265;10g em adolescentes e
adultos), o uso de N-acetilciste&#xED;na tamb&#xE9;m &#xE9; indicado, sendo a decis&#xE3;o de suspens&#xE3;o
do tratamento baseada na evolu&#xE7;&#xE3;o cl&#xED;nica e laboratorial<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>,</sup>
<xref rid="B18" ref-type="bibr">
<sup>18</sup>
</xref>
<sup>)</sup>. </p>
        <p>Outras situa&#xE7;&#xF5;es mais complexas envolvem a indica&#xE7;&#xE3;o de N-acetilciste&#xED;na ap&#xF3;s o uso
prolongado ou supraterap&#xEA;utico de paracetamol, quando a avalia&#xE7;&#xE3;o do risco
estratificado de hepatotoxicidade pelo nomograma de Rumack-Matthew n&#xE3;o &#xE9;
poss&#xED;vel<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>-</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. De maneira geral, recomenda-se o uso de N-acetilciste&#xED;na quando a
concentra&#xE7;&#xE3;o s&#xE9;rica de paracetamol est&#xE1; acima de 10&#xB5;g/mL ou AST&gt;50UI/L<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>,</sup>
<xref rid="B19" ref-type="bibr">
<sup>19</sup>
</xref>
<sup>)</sup>. Em pacientes com fal&#xEA;ncia hep&#xE1;tica, como o descrito, a N-acetilciste&#xED;na
tamb&#xE9;m atua possivelmente como antioxidante, melhorando o estado hemodin&#xE2;mico, o
consumo de oxig&#xEA;nio e o edema cerebral<sup>(</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. Pacientes com fal&#xEA;ncia hep&#xE1;tica induzida por paracetamol, seja por
overdoses isoladas, seja por doses supraterap&#xEA;uticas, devem receber N-acetilciste&#xED;na
intravenosa at&#xE9; que a encefalopatia se resolva ou apresentem melhora significativa
nos resultados da ALT, da RNI e da creatinina ou at&#xE9; o transplante
hep&#xE1;tico<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B17" ref-type="bibr">
<sup>17</sup>
</xref>
<sup>)</sup>. No presente caso, a infus&#xE3;o intravenosa cont&#xED;nua de N-acetilciste&#xED;na
mostrou-se efetiva, segura e sem efeitos adversos, mesmo em uso prolongado. </p>
        <p>Apesar de estudos em modelos experimentais sugerirem que a defici&#xEA;ncia de carnitina,
como causa ou consequ&#xEA;ncia, possa se associar &#xE0; hepatotoxicidade desencadeada pelo
paracetamol<sup>(</sup>
<xref rid="B20" ref-type="bibr">
<sup>20</sup>
</xref>
<sup>)</sup>, com os dados dispon&#xED;veis no presente relato (uma &#xFA;nica medida durante o
curso da fal&#xEA;ncia hep&#xE1;tica) seria especulativo inferir essa associa&#xE7;&#xE3;o. Estudos
cl&#xED;nicos s&#xE3;o necess&#xE1;rios para definir e caracterizar essa associa&#xE7;&#xE3;o de modo mais
preciso. No entanto, pode-se inferir que a triagem laboratorial, a evolu&#xE7;&#xE3;o e o
seguimento ambulatorial praticamente afastam a possibilidade de doen&#xE7;as gen&#xE9;ticas
associadas a altera&#xE7;&#xF5;es no transporte e no ciclo da carnitina, que podem evoluir com
fal&#xEA;ncia hep&#xE1;tica<sup>(</sup>
<xref rid="B21" ref-type="bibr">
<sup>21</sup>
</xref>
<sup>)</sup>. </p>
        <p>&#xC9; poss&#xED;vel concluir que o uso cont&#xED;nuo de paracetamol pode ocasionar hepatotoxicidade
grave em neonatos. A posologia espec&#xED;fica para neonatos de termo e prematuros deve
ser seguida, evitando-se o uso cont&#xED;nuo por mais de dois a tr&#xEA;s dias<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>,</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup>. </p>
      </sec>
    </body>
  </sub-article>
</article>
</pmc-articleset>
